Know what’s really happening at
City Therapeutics before you sign on.
- On the roadmap
- Biotech
- RNA Therapeutics
- Drug Discovery
City Therapeutics is engineering next-generation small interfering RNAs (siRNAs) to broaden the reach and potency of RNAi-based medicines. Backed by a top-tier investor syndicate and over $234 million in total funding, the Cambridge-based company is building a platform that could reshape how disease-driving genes are silenced.
How we do it.
Most "AI market intel" is a summarized crawl of press releases. This Altis research is built from our knowledge graph of sector expert calls, synthesized with public sources.
City Therapeutics
- Total Funding
- $234.5M
- Series B Round (June 2026)
- $99.5M
- Year Founded
- 2024
- Employee Count
- 79
- Headquarters
- Cambridge, Massachusetts, United States
- Funding Rounds
- 2
- Founder
- Sebastian Trousil
- LinkedIn Followers
- ~11K
Press reported
Altis Verified
What's in the report
Most "AI market intel" is a summarized crawl of press releases. This is what customers, competitors, and former employees actually told us.
Market Overview
Market structure, where the company sits, and growth drivers.
- market map
- Biotech landscape
- Biotech growth rate
- CAGR
Total Addressable Market
Bottom-up TAM / SAM / SOM.
- City Therapeutics TAM
- Biotech market size
- market opportunity
Company Overview
What the company does and how it operates.
- what does City Therapeutics do
- City Therapeutics product
- business model
Product / Go-to-Market
Product, GTM motion, ICP, and who buys.
- City Therapeutics customers
- who uses City Therapeutics
- City Therapeutics ICP
- go-to-market
Competitive Dynamics
The Altis Market Map and the Altis Win-Rate Index.
- City Therapeutics competitors
- City Therapeutics alternatives
- who competes with City Therapeutics
- City Therapeutics win rate
Customer Signals
Retention, satisfaction, and win/loss signals.
- City Therapeutics reviews
- City Therapeutics NRR
- City Therapeutics churn
- current customers
- switching costs
Investment Debates
Investment thesis, moat, bull/bear, and key risks.
- City Therapeutics investment thesis
- City Therapeutics moat
- bull case bear case
- City Therapeutics risk factors
Monetization & Financials
Business model, revenue model, and unit economics.
- City Therapeutics ARR
- City Therapeutics revenue
- City Therapeutics valuation
- unit economics
Team and culture
Founders, leadership, and org.
- City Therapeutics founders
- City Therapeutics CEO background
- leadership team
- headcount
Trusted by
Ready to see the full picture?
Profile based on structured company data, public funding records, and investor disclosures as of July 2026.